Regeneron Pharmaceuticals Inc. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY

Regeneron Pharmaceuticals Inc. lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 68.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,392,303 shares of the biopharmaceutical company’s stock after selling 3,052,142 shares during the quarter. Alnylam Pharmaceuticals makes up approximately 90.6% of Regeneron Pharmaceuticals Inc.’s portfolio, making the stock its largest holding. Regeneron Pharmaceuticals Inc. owned about 1.05% of Alnylam Pharmaceuticals worth $634,890,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ALNY. Root Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC bought a new position in Alnylam Pharmaceuticals during the third quarter valued at $27,000. Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals in the second quarter worth $30,000. ORG Partners LLC raised its stake in shares of Alnylam Pharmaceuticals by 70.2% in the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 33 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $37,000. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 2,242 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. The trade was a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,959 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72. Following the completion of the transaction, the executive vice president owned 31,769 shares in the company, valued at approximately $9,850,931.52. This trade represents a 5.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 36,578 shares of company stock worth $12,416,105. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $332.68 on Thursday. The company’s 50 day simple moving average is $369.58 and its two-hundred day simple moving average is $423.61. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The stock has a market capitalization of $44.12 billion, a PE ratio of 194.55 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). The firm had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.65) EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Needham & Company LLC decreased their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Barclays started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price objective for the company. Finally, Freedom Capital raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target on ALNY to $429 and maintained a “buy” rating, signaling meaningful upside from current levels and helping lift investor sentiment. Read More.
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $510 price target, a notably higher bull case that reinforces optimistic analyst views on Alnylam’s growth prospects. Read More.
• Positive Sentiment: Freedom Capital Markets issued an upgrade on ALNY, which added to the positive analyst chorus and likely contributed to upticks in trading interest. Read More.
• Neutral Sentiment: Several analyst notes trimmed near‑term targets or updated models but generally kept confidence in 2026 growth — a mixed signal that tempers both the bullish and bearish narratives. Read More.
• Neutral Sentiment: Independent valuation pieces describe a mixed picture: bullish fair‑value models versus share-price returns, suggesting some analysts still see long-term upside but valuation expectations vary. Read More.
• Neutral Sentiment: Reported short‑interest figures in the feeds show zero/NaN values and a 0.0 days‑to‑cover — likely a data/reporting artifact rather than actionable new short pressure; treat this as non‑conclusive until exchange data confirms.
• Negative Sentiment: Significant insider selling announced this week: CEO Yvonne Greenstreet sold 6,958 shares (~$310 avg) and several EVPs (including Kevin Fitzgerald, Jeffrey Poulton, Tolga Tanguler, Pushkal Garg) sold multiple blocks at ~$310–332, each trimming mid‑single‑digit percentages of their holdings. Large, clustered insider sales can weigh on near‑term sentiment even if executed for diversification or tax reasons. Read More.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.